Prof Eugene McCloskey MD, FRCPI

Professor in Adult Bone Disease and Honorary Consultant

Professor Eugene McCloskey

Metabolic Bone Centre
Sorby Wing
Northern General Hospital
Herries Road
Sheffield
S57AU
UK

Office: MB/D/24

Tel: +44 (0)114 271 4705
Fax: +44 (0)114 261 8775
Email: E.V.McCloskey@sheffield.ac.uk

Secretary: Gill Higginbottom
Tel: +44 (0)114 271 4705
Fax: +44 (0)114 261 8775

Biography

Born in Loughgiel, Northern Ireland, I studied medicine at Trinity College Dublin before arriving in Sheffield in 1985 via house officer posts in Ayrshire.


Research Interests

I developed my longstanding interest in metabolic bone diseases via an MRC Training Fellowship. My initial interests were in the field of malignant bone disease, but subsequently focussed on osteoporosis. I have been the principal investigator in a number of MRC and pharmaceutical industry-funded studies. I am an acknowledged expert in the fields of vertebral fracture definition, osteoporosis epidemiology as well as non-invasive assessments of bone strength and fracture risk. I have published over 150 peer-reviewed articles, book chapters, guidelines, and reviews.


Teaching Interests

I am the educational lead and teaching coordinator for Musculoskeletal Medicine across the various phases of the undergraduate curriculum at the University of Sheffield, as well as teaching on postgraduate courses (e.g. MSc in Molecular Medicine, Molecular and Cellular Basis of Disease module).


Professional Activities

I am currently secretary of the Bone Research Society, chair of the American Society for Bone and Mineral Research Ancillary Program Committee and a member of the National Specialty Group for Musculoskeletal Diseases.I also chair the Implementation Committee of the National Osteoporosis Guidance Group.


Current Projects

• FRAX and fracture risk assessment

• Interaction between physical and pharmaceutical interventions

Publications

Kayan, K., Johansson, H., Oden, A., Vasireddy, S., Pande, K., Orgee, J., Kanis, J.A., & McCloskey, E.V. (2009) Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporosis International 20: 2055-2061.

Johansson, H., Kanis, J.A., Oden, A., Johnell, O., & McCloskey, E. (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporosis International 20: 1675-1682.

McCloskey, E.V., Johansson, H., Oden, A., Vasireddy, S., Kayan, K., Pande, K., Jalava, T. & Kanis, J.A. (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study. Osteoporosis International 20: 811-817.

Boonen, S., Marin, F., Obermayer-Pietsch, B., Simões, M.E., Barker, C., Glass, E.V., Hadji, P., Lyritis, G., Oertel, H., Nickelsen, T., McCloskey, E.V. and EUROFORS Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. The Journal of Clinical Endocrinology and Metabolism 93: 852-860.

Kanis, J.A., Johnell, O., Oden, A., Johansson, H.,& McCloskey, E. (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis International 19:385-397.

McCloskey, E.V., Beneton, M., Charlesworth, D., Kayan, K., deTakats, D., Dey, A., Orgee, J., Ashford, R., Forster, M., Cliffe, J., Kersh, L., Brazier, J., Nichol, J., Aropuu, S., Jalava, T. & Kanis, J.A. (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. Journal of Bone and Mineral Research 22:135-141.